# Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

> **NCT07074977** · PHASE2 · RECRUITING · sponsor: **Galderma R&D** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Pruritus of Unknown Origin

## Interventions

- **DRUG:** nemolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07074977
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07074977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07074977, "Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07074977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*